First clinical trial finds CBD at 400mg and 800mg reduced cannabis use compared to placebo

In the first randomized clinical trial of CBD for cannabis use disorder, CBD at 400mg and 800mg daily was safe and more effective than placebo at reducing cannabis use, while CBD at 200mg was eliminated as ineffective.

Freeman, Tom P et al.·The lancet. Psychiatry·2020·Strong EvidenceRandomized Controlled Trial

CBD (1125)Addiction (1380)Quitting (221)

Quick Facts

Study Type

Randomized Controlled Trial

Evidence

Strong Evidence

Sample

N=82

What This Study Found

CBD 400mg reduced urinary THC metabolites by 94 ng/mL and increased abstinent days by 0.48 per week compared to placebo. CBD 800mg reduced metabolites by 72 ng/mL and increased abstinence by 0.27 days per week. CBD 200mg was eliminated as inefficacious at interim analysis.

Key Numbers

82 participants enrolled. CBD 400mg: THC-COOH decreased by 94.21 ng/mL (95% CI -161.83 to -35.56), abstinence increased by 0.48 days/week. 94% completed treatment. No severe adverse events.

How They Did This

Phase 2a double-blind, placebo-controlled, randomized adaptive Bayesian trial at University College London. 82 participants with cannabis use disorder were randomized to CBD 200mg, 400mg, 800mg, or placebo for 4 weeks. The 200mg dose was eliminated at interim analysis.

Why This Research Matters

No pharmacological treatment currently exists for cannabis use disorder. This trial provides the first clinical evidence that CBD could fill this gap, with the 400mg dose showing the strongest overall results.

The Bigger Picture

Using a non-intoxicating cannabis compound to treat cannabis addiction is a novel approach. The high completion rate (94%) and lack of severe side effects suggest CBD could be a practical treatment option worth pursuing in larger trials.

What This Study Doesn't Tell Us

Small sample size (82 total). Short treatment duration (4 weeks). Single site. The adaptive Bayesian design, while efficient, means the 200mg dose was tested in fewer participants.

Questions This Raises

?Would longer CBD treatment produce larger effects?
?Why did 400mg outperform 800mg?
?Would CBD help people with more severe cannabis dependence?
?What is the optimal duration of treatment?

Trust & Context

Key Stat:: CBD 400mg reduced THC metabolites by 94 ng/mL vs placebo
Evidence Grade:: Strong: randomized, double-blind, placebo-controlled trial with innovative adaptive Bayesian design, though limited by sample size.
Study Age:: Published in 2020 in The Lancet Psychiatry.
Original Title:: Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.
Published In:: The lancet. Psychiatry, 7(10), 865-874 (2020)
Authors:: Freeman, Tom P(51), Hindocha, Chandni(13), Baio, Gianluca(3), Shaban, Natacha D C, Thomas, Emily M, Astbury, Danica, Freeman, Abigail M, Lees, Rachel, Craft, Sam, Morrison, Paul D, Bloomfield, Michael A P, O'Ryan, Dominic, Kinghorn, Jane, Morgan, Celia J A, Mofeez, Ali, Curran, H Valerie
Database ID:: RTHC-02558

Evidence Hierarchy

Meta-Analysis / Systematic Review

Randomized Controlled TrialGold standard for testing treatments

This study

Cohort / Case-Control

Cross-Sectional / Observational

Case Report / Animal Study

Participants are randomly assigned to treatment or placebo groups to test cause and effect.

What do these levels mean? →

Frequently Asked Questions

How does CBD help with cannabis addiction?

The exact mechanism is not fully understood, but CBD may reduce cannabis cravings and withdrawal symptoms without producing intoxication. In this trial, participants who took CBD used less cannabis and had more abstinent days than those on placebo.

Why did 400mg work better than 800mg?

The trial found 400mg slightly outperformed 800mg on both primary outcomes, suggesting a possible inverted U-shaped dose response. However, both doses exceeded efficacy thresholds, and the sample was too small to definitively establish which dose is optimal.

Cite This Study

RTHC-02558·https://rethinkthc.com/research/RTHC-02558

APA

Freeman, Tom P; Hindocha, Chandni; Baio, Gianluca; Shaban, Natacha D C; Thomas, Emily M; Astbury, Danica; Freeman, Abigail M; Lees, Rachel; Craft, Sam; Morrison, Paul D; Bloomfield, Michael A P; O'Ryan, Dominic; Kinghorn, Jane; Morgan, Celia J A; Mofeez, Ali; Curran, H Valerie. (2020). Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.. The lancet. Psychiatry, 7(10), 865-874. https://doi.org/10.1016/S2215-0366(20)30290-X

MLA

Freeman, Tom P, et al. "Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.." The lancet. Psychiatry, 2020. https://doi.org/10.1016/S2215-0366(20)30290-X

RethinkTHC

RethinkTHC Research Database. "Cannabidiol for the treatment of cannabis use disorder: a ph..." RTHC-02558. Retrieved from https://rethinkthc.com/research/freeman-2020-cannabidiol-for-the-treatment

Access the Original Study

View on PubMed View via DOI

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.

← Back to Research Database